Ethical considerations arise when individuals who were contracted and paid to conduct a research study and write it up for publication, are denied authorship on a scholarly publication on the grounds that their work was contracted and paid for. Each of the various stakeholders should be considered. Researchers need to make sure that the contract recognizes their intellectual contribution and their right to be named as authors if and when the contracted study is published. If authorship disputes of published works arise, journal editors should have mechanisms in place for addressing such disputes. They should be able to see the contract and have all disputing parties agree to any changes in authorship. If the dispute cannot be resolved, the manuscript should be retracted. Contractors should develop a publication plan and include in the contract stipulations ensuring transparent and unambiguous authorship on any publication ensuing from contracted work. The International Committee of Medical Journal Editors and the Committee for Publication Ethics should update their guidance for authors to include advice regarding researchers involved in contracted work and how to resolve an authorship disputes around it.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11948-019-00173-5 | DOI Listing |
Alzheimers Dement (N Y)
January 2025
Alzheimer Center Amsterdam Neurology Vrije Universiteit Amsterdam, Amsterdam UMC VUmc Amsterdam The Netherlands.
Introduction: Recruitment of participants for intervention studies is challenging. We evaluated the effectiveness and efficiency of a participant recruitment campaign through an online registry for the FINGER-NL study, a multi-domain lifestyle intervention trial targeting cognitively healthy individuals aged 60-79 with dementia prevention potential. Additionally, we explored which recruitment strategy successfully reached individuals from underrepresented groups in research.
View Article and Find Full Text PDFAlzheimer Dis Assoc Disord
January 2025
Department of Neurobiology, Care Science and Society, Karolinska Institutet, Stockholm, Sweden.
Lung
January 2025
National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, UMR 754, ERN-LUNG, Lyon, France.
Purpose: In the INBUILD trial in patients with progressive pulmonary fibrosis (PPF), nintedanib slowed the decline in forced vital capacity (FVC) versus placebo, with a safety profile characterised mainly by gastrointestinal events. INBUILD-ON, the open-label extension of INBUILD, assessed the safety of nintedanib during longer-term treatment. Data on FVC were collected.
View Article and Find Full Text PDFCombined immune checkpoint blockade (ICB) and chemoradiation (CRT) is approved in patients with locally advanced cervical cancer (LACC) but optimal sequencing of CRT and ICB is unknown. NRG-GY017 (NCT03738228) was a randomized phase I trial of atezolizumab (anti-PD-L1) neoadjuvant and concurrent with CRT (Arm A) vs. concurrent with CRT (Arm B) in patients with high-risk node-positive LACC.
View Article and Find Full Text PDFBr J Anaesth
January 2025
Department of Anesthesiology, Center of Anesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Outcomes Research Consortium, Cleveland, OH, USA. Electronic address:
Background: Hypotension is associated with organ injury and death in surgical and critically ill patients. In clinical practice, treating hypotension remains challenging because it can be caused by various underlying haemodynamic alterations. We aimed to identify and independently validate endotypes of hypotension in big datasets of surgical and critically ill patients using unsupervised deep learning.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!